Annual SGA
$48.89 M
+$968.80 K+2.02%
December 31, 2023
Summary
- As of February 26, 2025, RLMD annual SGA is $48.89 million, with the most recent change of +$968.80 thousand (+2.02%) on December 31, 2023.
- During the last 3 years, RLMD annual SGA has risen by +$24.03 million (+96.63%).
- RLMD annual SGA is now at all-time high.
Performance
RLMD SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$11.86 M
+$3.76 M+46.46%
September 30, 2024
Summary
- As of February 26, 2025, RLMD quarterly SGA is $11.86 million, with the most recent change of +$3.76 million (+46.46%) on September 30, 2024.
- Over the past year, RLMD quarterly SGA has increased by +$2.18 million (+22.48%).
- RLMD quarterly SGA is now -18.77% below its all-time high of $14.60 million, reached on June 30, 2022.
Performance
RLMD Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$2.37 B
-$86.49 M-3.79%
September 30, 2024
Summary
- As of February 26, 2025, RLMD TTM SGA is -$2.37 billion, with the most recent change of -$86.49 million (-3.79%) on September 30, 2024.
- Over the past year, RLMD TTM SGA has dropped by -$2.41 billion (-5212.58%).
- RLMD TTM SGA is now -19556571.90% below its all-time high of -$12.10 thousand.
Performance
RLMD TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
RLMD Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +2.0% | +22.5% | -5212.6% |
| 3 y3 years | +96.6% | +37.0% | -7450.6% |
| 5 y5 years | +757.3% | +551.6% | -10000.0% |
RLMD Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +39.4% | -18.8% | +46.5% | -135.4% | at low |
| 5 y | 5-year | at high | +927.6% | -18.8% | +551.6% | -561.9% | at low |
| alltime | all time | at high | >+9999.0% | -18.8% | >+9999.0% | <-9999.0% | at low |
Relmada Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $11.86 M(+46.5%) | $41.72 M(-0.9%) |
| Jun 2024 | - | $8.10 M(-16.4%) | $42.10 M(-9.1%) |
| Mar 2024 | - | $9.68 M(-19.8%) | $46.28 M(-5.3%) |
| Dec 2023 | $48.89 M(+2.0%) | $12.08 M(-1.3%) | $48.90 M(+0.5%) |
| Sep 2023 | - | $12.24 M(-0.4%) | $48.65 M(+9.0%) |
| Jun 2023 | - | $12.29 M(-0.0%) | $44.62 M(-4.9%) |
| Mar 2023 | - | $12.29 M(+3.9%) | $46.93 M(-2.1%) |
| Dec 2022 | $47.93 M(+36.6%) | $11.83 M(+44.2%) | $47.93 M(+6.5%) |
| Sep 2022 | - | $8.21 M(-43.8%) | $45.00 M(-1.0%) |
| Jun 2022 | - | $14.60 M(+9.9%) | $45.45 M(+13.7%) |
| Mar 2022 | - | $13.28 M(+49.1%) | $39.98 M(+14.0%) |
| Dec 2021 | $35.08 M(+41.1%) | $8.91 M(+2.9%) | $35.08 M(+9.0%) |
| Sep 2021 | - | $8.66 M(-5.2%) | $32.19 M(+9.2%) |
| Jun 2021 | - | $9.13 M(+8.9%) | $29.48 M(+6.1%) |
| Mar 2021 | - | $8.38 M(+39.3%) | $27.78 M(+11.7%) |
| Dec 2020 | $24.87 M(+422.6%) | $6.02 M(+1.2%) | $24.87 M(+31.9%) |
| Sep 2020 | - | $5.95 M(-20.0%) | $18.85 M(+28.0%) |
| Jun 2020 | - | $7.43 M(+36.0%) | $14.72 M(+76.2%) |
| Mar 2020 | - | $5.47 M(+200.4%) | $8.35 M(+27.8%) |
| Dec 2019 | $4.76 M(-16.6%) | - | - |
| Sep 2019 | - | $1.82 M(+70.8%) | $6.53 M(+14.6%) |
| Jun 2019 | $5.70 M(+43.5%) | $1.07 M(-25.3%) | $5.70 M(+1.7%) |
| Mar 2019 | - | $1.43 M(-35.8%) | $5.61 M(+10.7%) |
| Dec 2018 | - | $2.22 M(+124.5%) | $5.07 M(+22.1%) |
| Sep 2018 | - | $989.70 K(+1.9%) | $4.15 M(+4.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2018 | $3.97 M(-32.9%) | $970.90 K(+10.0%) | $3.97 M(-13.6%) |
| Mar 2018 | - | $883.00 K(-32.4%) | $4.60 M(-16.5%) |
| Dec 2017 | - | $1.31 M(+60.2%) | $5.51 M(+0.4%) |
| Sep 2017 | - | $815.10 K(-49.0%) | $5.49 M(-7.4%) |
| Jun 2017 | $5.93 M(-40.8%) | $1.60 M(-10.8%) | $5.93 M(-13.1%) |
| Mar 2017 | - | $1.79 M(+39.8%) | $6.82 M(-4.8%) |
| Dec 2016 | - | $1.28 M(+2.4%) | $7.16 M(-24.5%) |
| Sep 2016 | - | $1.25 M(-49.7%) | $9.48 M(-5.1%) |
| Jun 2016 | $10.01 M(+8.5%) | $2.49 M(+16.4%) | $9.99 M(+10.5%) |
| Mar 2016 | - | $2.14 M(-40.7%) | $9.04 M(-1.8%) |
| Dec 2015 | - | $3.60 M(+104.3%) | $9.21 M(+16.6%) |
| Sep 2015 | - | $1.76 M(+14.7%) | $7.90 M(-13.6%) |
| Jun 2015 | $9.23 M(-23.8%) | $1.54 M(-33.2%) | $9.14 M(+20.2%) |
| Mar 2015 | - | $2.30 M(+0.4%) | $7.60 M(+43.4%) |
| Dec 2014 | - | $2.29 M(-23.6%) | $5.30 M(+75.4%) |
| Sep 2014 | - | $3.00 M(>+9900.0%) | $3.02 M(+5966.7%) |
| Jun 2014 | $12.11 M(>+9900.0%) | - | - |
| Feb 2014 | - | $3100.00(-78.6%) | $49.80 K(-2.9%) |
| Nov 2013 | - | $14.50 K(+16.9%) | $51.30 K(+11.3%) |
| Aug 2013 | $46.10 K(+234.1%) | $12.40 K(-37.4%) | $46.10 K(+7.7%) |
| May 2013 | - | $19.80 K(+330.4%) | $42.80 K(+67.2%) |
| Feb 2013 | - | $4600.00(-50.5%) | $25.60 K(+13.3%) |
| Nov 2012 | - | $9300.00(+2.2%) | $22.60 K(+69.9%) |
| Aug 2012 | $13.80 K | $9100.00(+250.0%) | $13.30 K(+216.7%) |
| May 2012 | - | $2600.00(+62.5%) | $4200.00(+162.5%) |
| Feb 2012 | - | $1600.00 | $1600.00 |
FAQ
- What is Relmada Therapeutics annual SGA?
- What is the all time high annual SGA for Relmada Therapeutics?
- What is Relmada Therapeutics annual SGA year-on-year change?
- What is Relmada Therapeutics quarterly SGA?
- What is the all time high quarterly SGA for Relmada Therapeutics?
- What is Relmada Therapeutics quarterly SGA year-on-year change?
- What is Relmada Therapeutics TTM SGA?
- What is the all time high TTM SGA for Relmada Therapeutics?
- What is Relmada Therapeutics TTM SGA year-on-year change?
What is Relmada Therapeutics annual SGA?
The current annual SGA of RLMD is $48.89 M
What is the all time high annual SGA for Relmada Therapeutics?
Relmada Therapeutics all-time high annual SGA is $48.89 M
What is Relmada Therapeutics annual SGA year-on-year change?
Over the past year, RLMD annual SGA has changed by +$968.80 K (+2.02%)
What is Relmada Therapeutics quarterly SGA?
The current quarterly SGA of RLMD is $11.86 M
What is the all time high quarterly SGA for Relmada Therapeutics?
Relmada Therapeutics all-time high quarterly SGA is $14.60 M
What is Relmada Therapeutics quarterly SGA year-on-year change?
Over the past year, RLMD quarterly SGA has changed by +$2.18 M (+22.48%)
What is Relmada Therapeutics TTM SGA?
The current TTM SGA of RLMD is -$2.37 B
What is the all time high TTM SGA for Relmada Therapeutics?
Relmada Therapeutics all-time high TTM SGA is -$12.10 K
What is Relmada Therapeutics TTM SGA year-on-year change?
Over the past year, RLMD TTM SGA has changed by -$2.41 B (-5212.58%)